Orca Bio is developing next-generation cell therapies that enhance transplant outcomes by utilizing precision-engineered cell products, specifically Orca-T and Orca-Q. The company aims to reduce the risks associated with traditional transplant procedures, providing patients with safer and more effective treatment options.
Funding
$375M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional bone marrow transplants carry significant risks, including graft-versus-host disease (GVHD) and opportunistic infections, due to the infusion of unselected donor cells that can attack the recipient's tissues or fail to provide adequate immune reconstitution. These complications can lead to prolonged hospitalizations, increased morbidity, and reduced long-term survival rates.
Solution
Orca Bio is developing precision cell therapies, Orca-T and Orca-Q, designed to improve transplant outcomes by selectively infusing specific types of donor cells. Orca-T aims to reduce GVHD by precisely controlling the composition of the graft, while Orca-Q is engineered to enhance immune reconstitution and minimize the risk of infections post-transplant. This targeted approach seeks to deliver the benefits of cell therapy with fewer of the life-threatening complications associated with conventional, less refined transplant procedures. By redefining the transplant process, Orca Bio strives to provide safer and more effective treatment options for patients.
Target Audience
The primary target audience includes patients with hematologic malignancies and other severe blood disorders who are eligible for hematopoietic stem cell transplantation, as well as transplant physicians and centers seeking to improve patient outcomes and reduce transplant-related complications.
Features
- Orca-T: Precision-engineered cell therapy designed to minimize graft-versus-host disease (GVHD).
- Orca-Q: Cell therapy engineered to enhance immune reconstitution and reduce the risk of post-transplant infections.
- Selective cell infusion: Precisely controlled composition of the graft to target specific therapeutic effects.